Related Experiment Video
Updated: Jan 10, 2026
Disorders of Erythrocytes
Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting
Eve D Aymong1, Michael J Curtis, Mostafa Youssef
1Cardiovascular Division, Department of Medicine, University of Calgary, Alberta, Canada.
Insights
Abciximab preserves coronary blood flow response to acetylcholine after stenting, suggesting it protects microvascular endothelial function and explains its clinical benefits in percutaneous coronary intervention (PCI).
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic events post-percutaneous coronary intervention (PCI).
- The precise mechanism behind abciximab's benefit, particularly regarding endothelial function, remains unclear.
- This study investigates the impact of abciximab on endothelium-dependent vasomotion following coronary stenting.
Purpose of the Study:
- To assess endothelium-dependent vasomotion after coronary stenting.
- To determine if abciximab alters the endothelial response to stimuli post-stenting.
- To elucidate the mechanism of abciximab's benefit in PCI.
Main Methods:
- 48 patients undergoing stenting (alone or with abciximab) and 31 controls were studied.
- Coronary blood flow (CBF) was measured using a Doppler wire after PCI.
- Vasomotor response was assessed using intracoronary infusions of acetylcholine (Ach) and adenosine.
Main Results:
- Ach-mediated increase in CBF was impaired after stenting compared to controls (41% vs 70%).
- The abciximab group showed a superior CBF response to Ach post-stenting (83%) versus stenting alone (41%).
- Abciximab administration was a strong predictor of preserved CBF response to Ach.
Conclusions:
- Abciximab preserves the acetylcholine-mediated coronary blood flow response after coronary stenting.
- This preservation of microvascular endothelial function may contribute to abciximab's clinical efficacy in PCI.
- Abciximab's protective effect on endothelial function offers a potential explanation for reduced ischemic events.
Background:
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab decreases ischemic events after percutaneous coronary intervention (PCI); however, the mechanism of this benefit has not been fully elucidated. The present study was designed to assess endothelium-dependent vasomotion after coronary stenting and to determine if abciximab alters this response.
Methods And Results:
The study group consisted of 48 patients (59+/-10 years of age) with discrete coronary stenoses who underwent stenting alone (n=28) or stenting plus abciximab (n=20). A control group consisted of 31 additional patients who had vasomotor testing on a non-PCI vessel. Coronary blood flow (CBF) was measured (0.014-inch Doppler wire) 30 minutes after uncomplicated PCI and in response to the intracoronary infusion of acetylcholine (Ach) (10(-7), 10(-6) mol/L Ach) and adenosine (24 microg). Ach-mediated increase in CBF was impaired after stent insertion when compared with the control group (41+/-52% versus 70+/-48%; P<0.05). The stenting plus abciximab group demonstrated a superior CBF response to Ach compared with the stenting alone group (83+/-93% versus 41+/-52%; P<0.05), with no difference between groups in the peak flow or percent change in flow to adenosine. By multivariate analysis, concomitant administration of abciximab was strongly predictive of the change in CBF to Ach (P<0.005).
Conclusions:
Abciximab preserves the CBF response to Ach after coronary stenting. The preservation of microvascular endothelial function may help explain the beneficial clinical effect of this agent in patients undergoing PCI.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:19Rh Blood Group
01:15Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
01:10Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...